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Other names: RBTN2 (rhombotin-2); RHOM2; 
RBTNL1 (rhombotin-like-1); TTG2 (T-cell 
translocation gene 2); LMO2 (LIM domain only 2) 
Location: 11p13 
Local order: telomere LMO1 - NUP98 (11p15) - 




LMO2 belongs to a multigene family, extremely well 
conserved during evolution, encoding proteins 
containing two cystein-rich regions referred to as LIM 
domains: LMO1 (11p15), LMO2 (11p13), LMO3 
(12p); 6 exons. 
Transcription 
3 transcripts: LMO2-a and LMO2-b encode the same 




Small cystein rich protein with two tandemly arranged 
Zinc binding LIM domain motifs: named Lom2; 158 
amino acids; 18 kDa; 48 % amino-acid identity with 
LMO1 protein. 
LMO2 contains two transcription activating domains 
(one in N-term, in a prolin-rich 19 amino acid region, 
one in C-term) and two LIM domains as transcription 
repressing domains, selectively inhibiting the N-term 
activation domain (no effect on the C-term domain). 
Expression 
Early expressed during development, in all tissues 
(roughly consistent level in central nervous system, low 
level in thymus). 
Strongly expressed in the precursors of mixed 
erythrocyte/macrophage/mast, erythrocyte, 
megakaryocyte, neutrophil and macrophage colonies, 
undetectable in the mature progeny. 
Expressed in early B-cells, in leukemias of both the
myeloid and lymphoid lineages. 
Nuclear marker in normal germinal center B-cells. Also 
expressed in endothelial cells. High expression in the 





Hematopoiesis: LMO2 directly interacts with the basic-
loop-helix protein TAL1/SCL and the GATA DNA 
protein GATA1. They form a transcriptional complex: 
LMO2 has no direct evidence in DNA binding capacity 
but could act as a bridging molecule bringing together 
different DNA binding factors (TAL1, LDB1, 
E12/E47, GATA1) that are essential for hematopoiesis 
(e.g. in the erythroid complex). This interaction is 
critical for the regulation of red blood cell development 
in early stages of hematopoiesis. TAL1 interacts 
specifically with the LIM domains of LMO2, which in 
turn binds LDB1. Because LMO2 can also bind to 
GATA2, a complex LMO2-GATA2 might occur at 
earlier stages of hematopoiesis when Gata1 is not  
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expressed. Lmo2 has a central role in adult 
hematopoietic pathway regulation, on bone marrow 
pluripotential precursor stem cell mainly. LMO2 and 
TAL1 are able to partially suppress myeloid 
differentiation. LMO2 also interacts with 
retinoblastoma-binding protein 2 and elf-2 (ets 
transcription factor). 
LMO2-c expression is regulated by GATA1 and PU.1; 
LMO2-c acts as an antagonist of LMO2-a/b, therefore 
blocking the transactivation of LMO2-a/b. 
In the brain, hBEX2, LMO2, NSCL2 and LDB1 could 
form a similar complex. 
Implicated in 
t(11;14)(p13;q11)/T-cell leukaemia → 
LMO2/ TCRD-A 
Disease 
Childhood T-cell ALL ; found in 5-10% of T-cell ALL. 
Cytogenetics 
A variant translocation t(7;11)(q35;p13) has been 
described. 
Abnormal Protein 
It was previously believed that LMO2 is activated after 
chromosomal translocation by association either the T-
cell receptor a/T-cell receptor d (14q11) or T-cell 
receptor b gene (7q35). Chromosome breakpoints occur 
25 kb upstream LMO2 gene, in a presumed 
transcriptional start site, inducing truncation of the 
promoter/control region and leading to inappropriate 
Lmo2 level especially in T-cells (abnormal T-cell 
differentiation). However, it becomes now very likey 
that removal of a negative regulatory element from the 
LMO2 locus, rather than juxtaposition to the TCRD 
enhancer, is the main determinant for LMO2 activation 
in the majority of t(11;14)(p13;q11) translocations. 
del(11)(p12p13) T-cell leukaemia 
Disease 
Childhood T-cell ALL; found in about 5% of T-cell 
ALL. 
Cytogenetics 
Cryptic deletion that varies in size. 
Abnormal Protein 
LMO2 is activated through a cryptic intrachromosomal 
deletion, del(11)(p12p13), in which a negative 
regulatory element (NRE), situated upstream of the 
LMO2 gene, is deleted. Removal of this NRE causes 
activation of the proximal promoter of the LMO2 gene 




Germinal center B-cell lymphomas 
Disease 
Diffuse large-B-cell lymphomas, follicular lymphomas, 
Burkitt lymphomas, less often in other haematological 
malignancies. 
Prognosis 
LMO2 expression, together with BCL6, FN1, CCND2, 
SCYA3, and BCL2 expressions, is a predictor of 
outcome in diffuse large-B-cell lymphoma. 
Prostate cancer 
Note: Expression of LMO2 is higher in prostate 
tumours samples than in the normal epithelium. 
Moreover, overexpression of LMO2 is significantly 
associated with advanced tumour stage, as well as with 
the development of distant metastasis. 
Oncogenesis 
LMO2 may play an important role in prostate cancer 
progression, possibly via repression of E-cadherin 
expression. 
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